253
Views
4
CrossRef citations to date
0
Altmetric
Original Article

A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma

, , &
Pages 351-360 | Received 11 May 1999, Accepted 01 Sep 1999, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Maen Hussein, Marina Maglakelidze, Donald A Richards, Marielle Sabatini, Todd A Gersten, Keith Lerro, Ivan Sinielnikov, Alexander Spira, Yili Pritchett, Joyce M Antal, Rajesh Malik & J Thaddeus Beck. (2021) Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Management and Research 13, pages 6207-6218.
Read now
Vicki A. Morrison, Edie A. Weller, Thomas M. Habermann, Shuli Li, Richard I. Fisher, Bruce D. Cheson & Bruce A. Peterson. (2017) Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leukemia & Lymphoma 58:8, pages 1814-1822.
Read now
Arthur P. Rabinowitz, Neil J. Weiner, Bruce S. Tronic, Moshe Fridman, Rebecca F. Liberman & David J. Delgado. (2006) Severe neutropenia in CHOP occurs most frequently in cycle 1: A predictive model. Leukemia & Lymphoma 47:5, pages 853-858.
Read now
Gary H. Lyman, Vicki A. Morrison, David C. Dale, Jeffrey Crawford, David J. Delgado & Moshe Fridman. (2003) Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy. Leukemia & Lymphoma 44:12, pages 2069-2076.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.